Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

To estimate biologic influence on heart failure (HF) risk in rheumatoid arthritis. Retrospective cohort (RECORD Study of Italian Society for Rheumatology) study on administrative healthcare databases. We identified 2527 patients treated with either etanercept (n = 1690) or abatacept (n = 837). HF incidence rate was higher in the abatacept cohort than in the etanercept cohort with a 2.38 (95% CI 1.08–5.27) crude competing risk HR (SHR) for abatacept of developing HF, not confirmed after adjustment for prespecified confounders (SHR 1.43; 95% CI 0.51–3.98). Abatacept, compared to etanercept, is prescribed to patients with a worse cardiovascular profile but does not increase the risk of developing HF, when confounding factors are accounted for.

Original languageEnglish
JournalRheumatology International
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Rheumatoid Arthritis
Hospitalization
Heart Failure
Rheumatology
Cohort Studies
Databases
Delivery of Health Care
Abatacept
Etanercept
Incidence

Keywords

  • Biologic
  • Cardiovascular
  • DMARDs
  • Epidemiology

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

@article{05d5652ab36f406e961c8f2df58ff8b5,
title = "Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept",
abstract = "To estimate biologic influence on heart failure (HF) risk in rheumatoid arthritis. Retrospective cohort (RECORD Study of Italian Society for Rheumatology) study on administrative healthcare databases. We identified 2527 patients treated with either etanercept (n = 1690) or abatacept (n = 837). HF incidence rate was higher in the abatacept cohort than in the etanercept cohort with a 2.38 (95{\%} CI 1.08–5.27) crude competing risk HR (SHR) for abatacept of developing HF, not confirmed after adjustment for prespecified confounders (SHR 1.43; 95{\%} CI 0.51–3.98). Abatacept, compared to etanercept, is prescribed to patients with a worse cardiovascular profile but does not increase the risk of developing HF, when confounding factors are accounted for.",
keywords = "Biologic, Cardiovascular, DMARDs, Epidemiology",
author = "Elena Generali and Greta Carrara and Marinos Kallikourdis and Gianluigi Condorelli and Alessandra Bortoluzzi and Scir{\`e}, {Carlo A.} and Carlo Selmi",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s00296-018-4196-9",
language = "English",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept

AU - Generali, Elena

AU - Carrara, Greta

AU - Kallikourdis, Marinos

AU - Condorelli, Gianluigi

AU - Bortoluzzi, Alessandra

AU - Scirè, Carlo A.

AU - Selmi, Carlo

PY - 2018/1/1

Y1 - 2018/1/1

N2 - To estimate biologic influence on heart failure (HF) risk in rheumatoid arthritis. Retrospective cohort (RECORD Study of Italian Society for Rheumatology) study on administrative healthcare databases. We identified 2527 patients treated with either etanercept (n = 1690) or abatacept (n = 837). HF incidence rate was higher in the abatacept cohort than in the etanercept cohort with a 2.38 (95% CI 1.08–5.27) crude competing risk HR (SHR) for abatacept of developing HF, not confirmed after adjustment for prespecified confounders (SHR 1.43; 95% CI 0.51–3.98). Abatacept, compared to etanercept, is prescribed to patients with a worse cardiovascular profile but does not increase the risk of developing HF, when confounding factors are accounted for.

AB - To estimate biologic influence on heart failure (HF) risk in rheumatoid arthritis. Retrospective cohort (RECORD Study of Italian Society for Rheumatology) study on administrative healthcare databases. We identified 2527 patients treated with either etanercept (n = 1690) or abatacept (n = 837). HF incidence rate was higher in the abatacept cohort than in the etanercept cohort with a 2.38 (95% CI 1.08–5.27) crude competing risk HR (SHR) for abatacept of developing HF, not confirmed after adjustment for prespecified confounders (SHR 1.43; 95% CI 0.51–3.98). Abatacept, compared to etanercept, is prescribed to patients with a worse cardiovascular profile but does not increase the risk of developing HF, when confounding factors are accounted for.

KW - Biologic

KW - Cardiovascular

KW - DMARDs

KW - Epidemiology

UR - http://www.scopus.com/inward/record.url?scp=85056312594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056312594&partnerID=8YFLogxK

U2 - 10.1007/s00296-018-4196-9

DO - 10.1007/s00296-018-4196-9

M3 - Article

AN - SCOPUS:85056312594

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

ER -